Compare Biogen Inc (BIIB) vs ArcelorMittal SA (MT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs ArcelorMittal SA — how do they compare? Biogen Inc trades at $202.7 (market cap $30.13B), while ArcelorMittal SA trades at $74.2 (market cap $55.88B). The key difference: ArcelorMittal SA is the larger of the two by market cap, and ArcelorMittal SA pays a 0.81% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | MT | |
|---|---|---|
Market Cap | $30.13B | $55.88B |
Sector | Health | Basic Materials |
52-Week High | $216.63 | $75.35 |
52-Week Low | $128.93 | $32.44 |
Enterprise Value | $37.20B | $65.45B |
Dividend Yield | — | 0.81% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →
